Heartflow enters its November 12 quarterly update with a broader clinical evidence base and an operating model that still has to translate fast adoption into durable economics. In Q2 2026, revenue reached $64.1 million, 48% above the prior-year period, and GAAP gross margin rose to 83.0%. Management raised full-year revenue guidance to $246 million to $250 million.
Utilization grew faster than sales. Revenue case volume increased 74% in Q2, and the company tied part of the gap to a larger clinic and office mix plus volume rebates. That contrast makes commercial conversion as important as raw case growth when assessing the next update.
Recent clinical data expanded the evidence for Heartflow's technology. In P4, 1,105 patients were randomized to CT-guided or IVUS-guided PCI planning. One-year outcomes met the study's non-inferiority standard for CT guidance. Median procedure time was 17 minutes shorter and contrast use was approximately 12% lower. The result supports workflow utility, while adoption pace and economics remain for management to demonstrate.
A separate DECIDE registry analysis compared more than 6,000 well-matched patients. Heartflow Plaque Analysis was associated with 34% fewer major cardiovascular events and half the myocardial-infarction rate at one year versus CCTA alone. The registry design supports a clinical association, not the same causal claim as a randomized commercial study.
With a stronger clinical evidence base, the November 12 release is a test of two separate questions: whether rising utilization is converting into revenue efficiently and whether gross-margin gains are reaching the broader cost base. The clearest public signals will be revenue growth, gross margin, operating loss, product mix, and any change to annual guidance. Qualitative commentary on adoption will matter most when paired with measurable operating detail.
The full Heartflow premium review examines the clinical evidence, conversion questions, financial context, and valuation considerations in greater depth.
Market analysis, not personalized investment advice.